Targeted genetic therapies for inherited disorders that affect both cardiac and skeletal muscle.
Journal article
Psaras Y. and Toepfer CN., (2023), Exp Physiol
Comparing the effects of chemical Ca2+ dyes and R-GECO on contractility and Ca2+ transients in adult and human iPSC cardiomyocytes.
Journal article
Robinson P. et al, (2023), J Mol Cell Cardiol, 180, 44 - 57
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.
Journal article
Margara F. et al, (2022), Sci Rep, 12
Human iPSC-CMs and in-silico technologies define mechanisms and accelerate targeted pharmacogenetics in hypertrophic cardiomyopathy
Preprint
Margara F. et al, (2022)
CalTrack: High-Throughput Automated Calcium Transient Analysis in Cardiomyocytes.
Journal article
Psaras Y. et al, (2021), Circ Res, 129, 326 - 341
Combining human-based in silico and in vitro models of inherited cardiac diseases for drug safety and efficacy evaluation
Journal article
Margara F. et al, (2021), JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 111
Defining Diverse Disease Pathomechanisms Across Thick And Thin Filament Hypertrophic Cardiomyopathy Variants
Conference paper
Toepfer C. et al, (2021), CIRCULATION RESEARCH, 129